Astrazeneca (AZN) Operating Leases (2019 - 2026)

Astrazeneca (AZN) has reported Operating Leases for 8 consecutive years, with -$1.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 25.84% year-over-year to -$1.5 billion; the TTM figure through Mar 2026 stood at -$1.5 billion (down 25.84% YoY), while the FY2025 annual figure was -$1.4 billion, down 227.67% from the prior year.
• Operating Leases came in at -$1.5 billion for Q1 2026 at Astrazeneca, down from -$1.4 billion in the prior quarter.
• The five-year high for Operating Leases was $1.1 billion in Q4 2024, with the low at -$1.5 billion in Q1 2026.
• Average Operating Leases over 5 years is -$655.2 million, with a median of -$744.0 million recorded in 2023.
• Across the five-year window, Operating Leases advanced 29.87% in 2024 and plunged 227.67% in 2025, its largest moves.
• Year by year, Operating Leases stood at $953.0 million in 2022, then fell by 10.07% to $857.0 million in 2023, then increased by 29.87% to $1.1 billion in 2024, then slumped by 227.67% to -$1.4 billion in 2025, then slipped by 5.91% to -$1.5 billion in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered -$1.5 billion, -$1.4 billion, and -$1.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.